Sanofi: FDA Approves Sanofi’s Admelog® (insulin lispro injection)

Home  >>  News  >>  Sanofi: FDA Approves Sanofi’s Admelog® (insulin lispro injection)

Sanofi: FDA Approves Sanofi’s Admelog® (insulin lispro injection)

On December 13, 2017, Posted by , In News, With Comments Off on Sanofi: FDA Approves Sanofi’s Admelog® (insulin lispro injection)
  • First FDA-approved follow-on mealtime insulin
  • Admelog (insulin lispro injection) 100 Units/mL will be available
    in U.S. in vial and SoloStar pen

Paris, France – December 11, 2017 – The U.S. Food and Drug Administration (FDA) has approved Sanofi’s Admelog®, the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime.

“Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes. Complementing our existing insulin portfolio, Admelog will offer a more affordable option for those who require control of their blood sugar levels at mealtime,” said Stefan Oelrich, Executive Vice President and Head, Global Diabetes and Cardiovascular, Sanofi. “The approval of Admelog is an important milestone for Sanofi in our mission to serve patients living with chronic diseases such as diabetes.”

Admelog is a rapid-acting insulin similar to Humalog®, another insulin lispro 100 Units/mL, currently approved in the U.S. The Admelog clinical development program involved more than 1,000 adults living with type 1 or type 2 diabetes. Admelog will be available in both vials and the SoloStar pen, which is the most-used disposable insulin pen platform in the U.S.

Admelog was also granted marketing authorization as a biosimilar, under the proprietary name, Insulin lispro Sanofi®, by the European Commission in July 2017.

What is Admelog (insulin lispro injection)?

Prescription Admelog is a fast-acting human insulin used to improve blood sugar control in adults with Type 2 diabetes and adults and children (3 years and older) with Type 1 diabetes.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Read press release here

Comments are closed.